Viking Therapeutics prices upsized $500 million offering of common stock and convertible senior notes
VKTX•Viking Therapeutics priced an upsized $500 million offering, comprising $275 million of common stock and $225 million of convertible senior notes.
1. Offering details
Viking Therapeutics said it priced an upsized $500 million offering, with $275 million in common stock and $225 million in convertible senior notes.
